You are here: Industry Insights > Novartis

News List

Novartis Announces New Crizanlizumab Data Analysis in Sickle Cell Disease americanpharmaceuticalreview
December 04, 2018
New data from a post hoc analysis of the Phase II SUSTAIN study of crizanlizumab -- a once-a-month, humanized anti-P-selectin monoclonal antibody infusion being investigated.....
FDA grants priority review to Novartis' filing seeking clearance of gene therapy for spinal muscular atrophy firstwordpharma
December 03, 2018
Novartis said Monday that the FDA granted priority review to an application seeking approval of Zolgensma (onasemnogene abeparvovec) for the treatment of spinal muscular atrophy (SMA) Type 1, with the agency setting a target data in May next year.
Novartis plans UK headquarters move to London pharmaphorum
November 30, 2018
Novartis is on the move in the UK, relocating its national headquarters from Frimley in Surrey to London to get closer to the capital’s emerging life sciences cluster.
Novartis Announces EU Approval of Gilenya americanpharmaceuticalreview
November 30, 2018
Novartis announced the European Commission (EC) has approved Gilenya (fingolimod) for the treatment of children and adolescents 10 to 17 years old with relapsing-remitting forms
Novartis' Gilenya scores paediatric EU approval for advanced relapsing-remitting MS pharmafile
November 30, 2018
Novartis has announced that Gilenya (fingolimod) has received marketing authorisation from the European Commission for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS) in patients aged between 10 and 17 years old...
EU approves Gilenya for paediatric MS pharmatimes
November 30, 2018
European regulators have approved Novartis’ Gilenya for the treatment of children and adolescents from 10 to 17 years old with relapsing-remitting forms of multiple sclerosis (RRMS).
Novartis to move UK headquarters to London pharmatimes
November 29, 2018
Novartis is moving its UK headquarters to London, in a multi-million pound investment in UK life sciences, which will be complete by January 2020.
Novartis scores EU nod for gene therapy Luxturna fiercepharma
November 28, 2018
It’s been almost a year since Spark Therapeutics won a groundbreaking gene therapy approval in the U.S. for Luxturna, and now its marketing partner Novartis has done the same across the pond.
Alcon held its first Capital Markets Day for investors and analysts worldpharmanews
November 28, 2018
Alcon will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of Novartis to execute a tax-neutral, 100% spinoff of the Alcon business.
Abeona Therapeutics Announces CEO Transition firstwordpharma
November 27, 2018
Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page